Pharmacology Biochemical Pharmacology
Znf667 shields the heart by switching off Pcsk6-driven autophagy
- In heart-attack patients treated with primary PCI, circulating PCSK6 was higher and tracked with injury markers; it also rose in reperfused mouse myocardium and hypoxia-reperfused cardiomyocytes.
- Silencing Pcsk6 dampened autophagy and shrank infarct size in mice, while overexpressing it boosted autophagy and lowered cell viability.
- The transcription factor Znf667, reduced after hypoxia-reperfusion, represses the Pcsk6 promoter; restoring it protected the heart, and this was undone by Pcsk6, with NF-kB signalling implicated.
Elevated serum PCSK6 after PCI is a correlation, not proof it drives injury, and autophagy in reperfusion is notoriously double-edged: inhibit it at the wrong time and you lose protective flux. Before chasing Znf667, I'd want autophagic flux assays (with bafilomycin) and timing of Pcsk6 knockdown relative to reperfusion. A transcription factor is also a hard drug target; a Pcsk6 inhibitor is the more tractable test.
Paper: Biochemical Pharmacology ↗ Blockage of Pcsk6-mediated autophagy is involved in the protection of Znf667 against myocardial ischemia/reperfusion injury